CORSIZ 100 tablets

Form

tableti

Pack

100

CORSIS General Description: International Nonproprietary Name: Ethyl ester of alpha-bromoisovaleric acid, Phenobarbital, Peppermint oil; Main physical and chemical properties: White or almost white, with inclusions, round, flat, uncoated tablets with a bevel, with a specific odor. Composition: 1 uncoated tablet contains: Ethyl ester of alpha-bromoisovaleric acid _ 8.2 mg, Phenobarbital _ 7.5 mg, Peppermint oil _ 0.58 mg. Excipients: Beta-cyclodextrin, Potato starch, Lactose monohydrate, Microcrystalline cellulose, Magnesium stearate. Dosage form: Uncoated tablets. Pharmacological group: Hypnotic and sedative. Pharmacological properties: CORSIS is a sedative, vasodilator, antispasmodic agent that helps reduce the excitability of the central nervous system. The preparation has a calming effect, it facilitates the natural process of falling asleep. The ethyl ester of alpha-bromoisovaleric acid in the tablet has a sedative and antispasmodic effect similar to valerian extract, and in high doses, it also exhibits a mild hypnotic effect. Phenobarbital has a sedative and moderate antispasmodic effect. Peppermint oil reflexively dilates blood vessels and has an antispasmodic effect. See blog: What is CORSIS used for? — What to know before taking the preparation Indications: · Neurosis, excitability; · Insomnia, difficulty falling asleep; · Hypertensive disease and vegetative-vascular dystonia (as part of complex therapy); · Mild coronary spasm, tachycardia; · Spasm of the gastrointestinal tract organs caused by neurovegetative disorders (as an antispasmodic). Method of administration and dosage: The dosage and duration of the treatment regimen are determined by the attending physician individually for each patient. In adults, 1-2 tablets are usually prescribed 2-3 times a day before meals. In case of tachycardia and coronary spasm, the single dose can be increased to 3 tablets. Side effects: CORSIS is characterized by good tolerability. In isolated cases, the following side effects may occur: From the digestive system: constipation, feeling of heaviness in the epigastric region, with prolonged use – liver dysfunction, nausea, vomiting; From the nervous system: weakness, ataxia, impaired coordination of movements, nystagmus, hallucinations, paradoxical excitation, decreased concentration of attention, fatigue, delayed reactions, headache, cognitive impairment, drowsiness, mild dizziness; From the hematopoietic organs: anemia, thrombocytopenia, agranulocytosis; From the cardiovascular system: arterial hypotension, bradycardia; From the immune system: hypersensitivity reactions, including angioneurotic edema, allergic reactions (skin rash, itching, urticaria); From the skin and mucous membranes: Stevens-Johnson syndrome, toxic epidermal necrolysis; From the musculoskeletal system: with prolonged use of preparations containing phenobarbital, there is a risk of impaired osteogenesis; prolonged use of bromine-containing preparations can cause bromine intoxication, characterized by: central nervous system depression, depression, impaired consciousness, ataxia, apathy, conjunctivitis, rhinitis, lacrimation, acne or purpura. Side effects are reversible and disappear easily with dose reduction or discontinuation of treatment. If a side effect not listed in the instructions for use occurs, the patient should consult a doctor. Contraindications: Hypersensitivity to any component of the preparation; severe liver and/or kidney dysfunction; hepatic porphyria; severe heart failure. Interactions with medicinal products and other types of interactions: Concomitant administration of CORSIS and other central nervous system depressants may enhance their effects. The effect of CORSIS is enhanced by the use of valproic acid preparations and alcohol. Phenobarbital induces liver enzymes and, therefore, may accelerate the metabolism of drugs that are metabolized in the liver (indirect anticoagulants, cardiac glycosides, antimicrobial, antiviral, antifungal, antiepileptic, anticonvulsant, psychotropic drugs, oral antidiabetic drugs, hormonal, immunosuppressive, cytostatic, antiarrhythmic, antihypertensive drugs, and others). Phenobarbital enhances the effect of analgesic and local anesthetic agents. MAO inhibitors prolong the effect of phenobarbital. Rifampicin may reduce the effect of phenobarbital. Concomitant use of phenobarbital and gold preparations increases the risk of kidney damage. Concomitant use of phenobarbital and zidovudine increases the toxicity of both drugs. CORSIS increases the toxicity of methotrexate. Overdose: Overdose is possible with frequent or prolonged use, associated with the accumulation of its constituent components. Prolonged and constant use can lead to drug dependence, withdrawal syndrome, psychomotor agitation. Symptoms: Respiratory depression; central nervous system depression; cardiovascular depression, including rhythm disturbances, decreased blood pressure; nausea, weakness, decreased temperature, decreased diuresis. Treatment: Symptomatic therapy. Pregnancy and lactation: The use of the preparation during pregnancy and breastfeeding is not allowed. Special instructions: Alcohol consumption is prohibited when using the preparation. Phenobarbital in the composition of the medicinal product may cause a risk of developing Stevens-Johnson and Lyell's syndrome, which is expected in the first weeks of treatment. If chest pain does not stop after taking the preparation, medical consultation is necessary to rule out acute coronary syndrome. The preparation should be used with caution in arterial hypotension, hyperkinesis, hyperthyroidism, adrenal hypofunction, acute and persistent pain, acute drug intoxication. There is no data on the use of CORSIS in children, so the preparation is not used in pediatric practice. The preparation contains lactose, so the use of CORSIS is not recommended in patients with hereditary intolerance to lactose-galactose. Effect of the preparation on the ability to drive vehicles and operate mechanisms: When using the preparation, it is necessary to avoid activities that require attention and rapid psychomotor reactions. Packaging: 10 tablets in a blister, 10 blisters in a cardboard box. Storage conditions: Store at a temperature not exceeding 25ºC, protected from light and out of reach of children. In case of any defect found during visual inspection, the preparation should not be taken. 2 years. The preparation should not be used after the expiry date indicated on the packaging. Pharmacy dispensing condition: Pharmaceutical product group III, available without a prescription.